Extended treatment of abrocitinib: evaluation of efficacy and safety in chronic actinic dermatitis

Key Points

• Abrocitinib shows effectiveness in managing chronic actinic dermatitis (CAD), providing a potential new treatment option.
• The key factors influencing treatment success include interleukin-13 (IL-13) and CCL-4 expression levels in the patients.
• Evaluation was based on comprehensive data analysis to assess both efficacy and safety outcomes.
• The findings highlight the need for further exploration of abrocitinib as a treatment for chronic actinic dermatitis.

Abstract